Trial Outcomes & Findings for A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction (NCT NCT00571922)

Results Overview

Recruitment status

COMPLETED

Study phase

PHASE1/PHASE2

Target enrollment

72 participants

Primary outcome timeframe

7 day

Results posted on

2017-03-24

Participant Flow

Participant milestones

Participant milestones
Measure	Acamprosate Acamprosate: 2 gr/day (333 mg, TID)	Placebo placebo: matching placebo
Overall Study STARTED	36	36
Overall Study COMPLETED	0	0
Overall Study NOT COMPLETED	36	36

Reasons for withdrawal

Reasons for withdrawal
Measure	Acamprosate Acamprosate: 2 gr/day (333 mg, TID)	Placebo placebo: matching placebo
Overall Study Completion unknown	36	36

Baseline Characteristics

A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Placebo n=36 Participants placebo: matching placebo	Acamprosate n=36 Participants Acamprosate: 2 gr/day (333 mg, TID)	Total n=72 Participants Total of all reporting groups
Age, Categorical <=18 years	NA Participants n=7 Participants	NA Participants n=5 Participants	NA Participants n=5 Participants
Age, Categorical Between 18 and 65 years	NA Participants n=7 Participants	NA Participants n=5 Participants	NA Participants n=5 Participants
Age, Categorical >=65 years	NA Participants n=7 Participants	NA Participants n=5 Participants	NA Participants n=5 Participants
Sex: Female, Male Female	NA Participants n=7 Participants	NA Participants n=5 Participants	NA Participants n=5 Participants
Sex: Female, Male Male	NA Participants n=7 Participants	NA Participants n=5 Participants	NA Participants n=5 Participants

PRIMARY outcome

Timeframe: 7 day

Population: PI passed away, data is unavailable.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 7 day

Population: PI passed away, data is unavailable

Outcome measures

Outcome data not reported

Adverse Events

Acamprosate

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Placebo

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

The Office of Clinical Trials

NYU Langone Medical Center

Phone: 212.263.4210

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place